Ocular adverse events associated with GLP-1 receptor agonists: a Real-World Study Based on the FAERS database and network pharmacology

This study evaluates the risk of ocular adverse events (AEs) associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) by analyzing data from the FDA Adverse Event Reporting System (FAERS) and employing network pharmacology methods.